1
NVS
Novartis is an innovative medicines company that researches, develops, manufactures, and markets branded prescription pharmaceuticals across therapeutic areas such as cardiovascular, renal, metabolic diseases, immunology, neuroscience, and oncology. Its primary revenue is generated from the sale of these pharmaceutical products to wholesalers, health systems, and government agencies.
Novartis Ag
Pharmaceuticals
293.38 Bn
153.75
+1.74%
+19.06%
19.27
5.55
268.04 Bn
2
AZN
AstraZeneca is a global biopharmaceutical company that discovers, develops, and markets branded prescription medicines. Its revenue is primarily driven by the sale of branded pharmaceutical products such as Tagrisso, Farxiga, and Symbicort across various therapeutic areas.
Astrazeneca
Pharmaceuticals
266.60 Bn
172.00
+0.31%
+2.31%
25.23
4.49
237.24 Bn
3
AMGN
Amgen is explicitly described as a leading independent biotechnology company that researches, develops, and commercializes therapies derived from biological science. Its revenue is generated from the sale of therapeutic medicines such as Enbrel and Repatha, which are biologic products.
Amgen
Biotechnology
240.37 Bn
444.63
+1.22%
+52.71%
27.69
6.35
197.46 Bn
4
BMY
Bristol Myers Squibb is a large pharmaceutical firm that discovers, develops, and markets a wide portfolio of branded prescription medicines such as Eliquis, Sprycel, and Abraxane. Its revenue is primarily generated from the sale of these innovative branded pharmaceuticals across multiple therapeutic areas.
Bristol Myers Squibb
Pharmaceuticals
125.85 Bn
61.61
+0.21%
+41.99%
13.56
2.56
77.13 Bn
5
MRNA
Moderna is a biotechnology company that researches and commercializes therapies derived from biological science, specifically messenger RNA (mRNA). Its revenue is generated from the sale of biologic products like Spikevax and mRESVIA, as well as collaboration and licensing revenue.
Moderna
Biotechnology
79.34 Bn
198.85
-0.62%
+645.87%
-26.35
37.26
62.37 Bn
6
TAK
Takeda is a global pharmaceutical company that develops and markets branded prescription drugs across multiple therapeutic areas. Its revenue is driven by branded products such as ENTYVIO for inflammatory bowel disease and VYVANSE for ADHD.
Takeda Pharmaceutical
Pharmaceuticals
65.02 Bn
20.43
+0.89%
+44.18%
111.27
1.37
40.27 Bn
7
ARGX
Argenx is a biopharmaceutical company that develops and commercializes antibody-based therapeutics, such as VYVGART, which is an FcRn inhibitor. Its revenue is derived from the sale of these biologic products and from milestone payments and royalties from collaborations with partners like Zai Lab and AbbVie.
Argenx Se
Biotechnology
53.80 Bn
869.33
-0.50%
+4.76%
28.81
9.29
54.07 Bn
8
ALC
2nd
Alcon develops and markets branded prescription pharmaceuticals for ocular health, including Rocklatan and Rhopressa for the treatment of glaucoma.
Alcon
Pharmaceuticals
34.12 Bn
70.00
-0.26%
-8.02%
53.25
3.17
25.21 Bn
9
VTRS
Viatris is described as one of the largest providers of generic medicines globally, generating significant revenue from simple and complex generics, biosimilars, and specialty generics. The profile explicitly highlights its position as a major player in the generic drug market competing with Teva and Sandoz.
Viatris
Generic Drugs
21.01 Bn
18.29
+1.61%
+75.53%
-53.11
1.48
16.82 Bn
10
BAX
2nd
Baxter has a dedicated Pharmaceuticals segment that generates revenue from the sale of specialty injectable pharmaceuticals and inhaled anesthetics, which fall under specialty pharmaceuticals.
Baxter International
Generic Drugs
13.07 Bn
25.29
-0.08%
+9.15%
-12.13
2.32
5.02 Bn
11
MDGL
Madrigal Pharmaceuticals is a biopharmaceutical company that developed Rezdiffra (resmetirom), a thyroid hormone receptor beta agonist, and maintains a pipeline of biologics including GLP-1 receptor agonists and siRNA programs. Its revenue is derived from the sale of these biology-based therapies for the treatment of MASH.
Madrigal Pharmaceuticals
Biotechnology
12.76 Bn
437.74
+0.81%
+0.45%
-39.47
9.99
9.09 Bn
12
FMS
2nd
The company develops and markets renal pharmaceuticals, specifically mentioning erythropoietin stimulating agents, iron sucrose, and phosphate binders.
Fresenius Medical Care AG
Pharmaceuticals
12.71 Bn
22.76
+0.35%
-16.32%
11.98
1.18
5.05 Bn
13
ABVX
Abivax is a clinical-stage biotechnology company focused on discovering and developing therapeutics for chronic inflammatory diseases, specifically ulcerative colitis and Crohn's disease. Its revenue currently comes from research collaborations, licensing agreements, and grant funding, which is characteristic of the H-02 biotechnology classification.
Abivax
Biotechnology
6.79 Bn
86.50
-1.72%
-8.79%
-12.94
-79.40
3.70 Bn
14
HIMS
2nd
The company sells and fulfills generic, brand name, and compounded medications through its own pharmacies and partner pharmacies.
Hims & Hers Health
Generic Drugs
6.43 Bn
27.58
-0.40%
-42.82%
-45.58
2.51
3.67 Bn
15
BLTE
Belite Bio is a clinical-stage company developing branded prescription drugs, specifically oral small molecules like tinlarebant (LBS 008) and LBS 009. These candidates target therapeutic areas such as Stargardt disease, geographic atrophy, and metabolic disorders like type 2 diabetes.
Belite Bio
Pharmaceuticals
5.64 Bn
143.35
-2.70%
+52.79%
-63.51
—
4.89 Bn
16
GRFS
Grifols is a global producer of plasma derivatives, manufacturing biologic therapies such as immunoglobulins, albumin, and clotting factors (Factor VIII and IX). These are recombinant or plasma-derived proteins, which falls squarely under the biotechnology classification for therapies derived from biological science.
Grifols
Biotechnology
5.39 Bn
7.92
+4.76%
-15.57%
11.87
0.63
1.86 Bn
17
PTCT
PTC Therapeutics is a biopharmaceutical company that develops and commercializes therapies derived from biological science for rare diseases. Its revenue is generated from the sale of biologic-based products such as Evrysdi for spinal muscular atrophy and Upstaza for aromatic L-amino decarboxylase deficiency.
Ptc Therapeutics
Biotechnology
5.09 Bn
61.07
+0.79%
-8.96%
-134.37
5.11
-2.60 Bn
18
INDV
Indivior develops and markets branded prescription pharmaceuticals, specifically SUBLOCADE and SUBOXONE Film, for the treatment of opioid use disorder. Its revenue is derived from the sale of these branded medications to healthcare providers, pharmacies, and distributors.
Indivior Pharmaceuticals
Pharmaceuticals
4.08 Bn
34.56
+0.26%
+39.47%
11.64
3.10
3.09 Bn
19
ARQT
Arcutis is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically targeting immune-mediated dermatological conditions. Its revenue is generated from the sales of ZORYVE products and collaboration/milestone payments from partners like Huadong and Sato.
Arcutis Biotherapeutics
Biotechnology
4.00 Bn
31.81
+1.96%
+61.97%
144.97
8.91
3.42 Bn
20
LEGN
Legend Biotech focuses on the development and commercialization of CAR T therapies, specifically CARVYKTI for multiple myeloma, which are engineered cell therapies. The company's core platform involves proprietary llama-derived single-domain antibody technology and dual-binding CAR design to modify cells for oncology treatment.
Legend Biotech
Gene and Cell Therapy
3.76 Bn
20.39
+5.81%
-36.52%
-43.46
3.13
1.48 Bn
21
OGN
Organon's primary revenue comes from the sale of branded prescription pharmaceuticals, specifically its Women's Health segment featuring products like Nexplanon and NuvaRing. The company markets these branded medicines across therapeutic areas including contraception, fertility, and cardiovascular health.
Organon
Pharmaceuticals
3.61 Bn
13.76
+0.00%
+94.90%
17.27
0.59
115.59 Mn
22
RGC
Regencell Bioscience Holdings focuses on the research, development, and commercialization of a standardized Traditional Chinese Medicine (TCM) formula for the treatment of ADHD and ASD. The company intends to generate revenue from the sale of these branded pharmaceutical products once they receive regulatory approval.
Regencell Bioscience Holdings
Pharmaceuticals
3.35 Bn
6.76
-11.86%
-59.06%
-285.72
—
3.66 Bn
23
TLX
Telix is a biopharmaceutical company that develops and commercializes therapies and diagnostics derived from biological science, specifically antibody-based radiopharmaceuticals like Illuccix and Gozellix. Its core business involves the research and commercialization of biologic-based drug discovery for precision oncology.
Telix Pharmaceuticals
Biotechnology
3.05 Bn
8.99
-1.75%
-17.90%
—
—
2.01 Bn
24
DNLI
Denali Therapeutics is a biotechnology company developing therapies derived from biological science, specifically using its TransportVehicle platform to deliver antibodies, enzymes, and oligonucleotides. Its current revenue is derived from collaboration and milestone payments from partners like Biogen, Takeda, and Sanofi.
Denali Therapeutics
Biotechnology
2.98 Bn
18.66
+1.36%
+15.11%
-7.04
998.94
185.95 Mn
25
GMAB
Genmab is a biotechnology company that develops and commercializes antibody-based therapies, such as epcotamab and tisotumab vedotin. Its revenue is derived from biologic product sales, royalties from partnered biologics like daratumumab and rybrevant, and milestone payments from collaborations with partners like AbbVie and BioNTech.
Genmab A
Biotechnology
2.87 Bn
44.69
+2.06%
+53.94%
3.27
0.72
-2.48 Bn